PRPH · ProPhase Labs, Inc.
$0.03
-0.01 (-25.00%)
At close · Aug 17
Going-concern doubt
— flagged Jun 30, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. Management’s plans do not alleviate this substantial doubt.”View the 10-Q filed Jun 30, 2026
Market Cap
$560,641
Shares
14.02M
ProPhase Labs, Inc. Earnings Call Transcripts
Every quarterly earnings call for ProPhase Labs, Inc. (PRPH) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲774.3%
$45.14M
$10.59M
'21 Q4
22-03-30
▲210.5%
$47.50M
$12.49M
'22 Q1
22-05-13
▲219.8%
$29.10M
$7.45M
'22 Q2
22-08-11
▲154.7%
$24.20M
$968,000
'22 Q3
22-11-10
▼51.6%
$21.85M
−$2.44M
'22 Q4
23-03-28
▼59.4%
$19.30M
$550,000
'23 Q1
23-05-11
▼54.6%
$13.22M
−$3.44M
'23 Q2
23-08-10
▼65.4%
$8.37M
−$5.14M
'23 Q3
23-11-09
▼127%
$
−$8.75M
'23 Q4
24-03-15
▼87.8%
$2.36M
−$6.26M
'24 Q1
24-05-09
▼88.6%
$1.50M
−$6.15M
'24 Q2
24-08-14
▼83.1%
$1.42M
−$6.59M
'24 Q3
24-11-13
·
$1.49M
−$34.36M
'24 Q4
25-03-31
▼39.3%
$1.43M
$3.97M
'25 Q1
25-05-20
▼17.1%
$1.25M
−$4.47M
'25 Q2
25-08-13
LATEST
▼37.6%
$883,000
−$6.84M
'25 Q3
25-11-19
Earnings call
FY25 · Q3
2025-11-19
ProPhase Labs, Inc. Q3 FY2025 Earnings Call
Confident tone
Crown Medical Collections / COVID claims recovery
Proxy voting and reverse stock split
Market cap vs. underlying value disconnect
Revenue
$883,000
▼ 37.6% YoY Diluted EPS
$-1.60
Gross margin
-13.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-13
ProPhase Labs, Inc. Q2 FY2025 Earnings Call
Confident tone
BE-Smart esophageal cancer test commercialization
Crown Medical COVID receivables litigation
BE-Smart patent protection
Revenue
$1.25M
▼ 17.1% YoY Diluted EPS
$-1.10
Gross margin
58.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-20
ProPhase Labs, Inc. Q1 FY2025 Earnings Call
Revenue
$1.43M
▼ 39.3% YoY Diluted EPS
$1.13
Gross margin
36.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
ProPhase Labs, Inc. Q4 FY2024 Earnings Call
Revenue
$1.49M*
Gross margin
-10.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
ProPhase Labs, Inc. Q3 FY2024 Earnings Call
Confident tone
DNA Complete and DNA Expand
Prophase subsidiaries (Equivir, Legends XL)
Esophageal cancer test (b Smart)
Revenue
$1.42M
▼ 83.1% YoY Diluted EPS
$-3.50
Gross margin
15.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
ProPhase Labs, Inc. Q2 FY2024 Earnings Call
Confident tone
BE-Smart Esophageal Cancer Test
Pharmaloz growth and seasonality
Nebula Genomics strategy
Revenue
$1.50M
▼ 88.6% YoY Diluted EPS
$-3.30
Gross margin
-10.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
ProPhase Labs, Inc. Q1 FY2024 Earnings Call
Positive tone
Nebula esophageal cancer test (BE-Smart)
Pharmaloz growth and strategic alternatives
Equivir and other pipeline products
Revenue
$2.36M
▼ 87.8% YoY Diluted EPS
$-3.60
▼ 1300% YoY Gross margin
-2.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-15
ProPhase Labs, Inc. Q4 FY2023 Earnings Call
Confident tone
Competitive positioning vs. labs and ancestry testing
Pharmaloz manufacturing growth
Nebula Genomics and whole genome sequencing
Revenue
$*
▼ 127% YoY Gross margin
63.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
ProPhase Labs, Inc. Q3 FY2023 Earnings Call
Revenue
$8.37M
▼ 65.4% YoY Diluted EPS
$-3.00
▼ 600% YoY Gross margin
27.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
ProPhase Labs, Inc. Q2 FY2023 Earnings Call
Revenue
$13.22M
▼ 54.6% YoY Diluted EPS
$-2.00
▼ 150% YoY Gross margin
48.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
ProPhase Labs, Inc. Q1 FY2023 Earnings Call
Revenue
$19.30M
▼ 59.4% YoY Diluted EPS
$0.30
▼ 95.6% YoY Gross margin
54.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-28
ProPhase Labs, Inc. Q4 FY2022 Earnings Call
Revenue
$21.85M*
▼ 51.6% YoY Gross margin
51.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
ProPhase Labs, Inc. Q3 FY2022 Earnings Call
Revenue
$24.20M
▲ 154.7% YoY Diluted EPS
$0.60
Gross margin
49.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
ProPhase Labs, Inc. Q2 FY2022 Earnings Call
Revenue
$29.10M
▲ 219.8% YoY Diluted EPS
$4.00
Gross margin
64.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-13
ProPhase Labs, Inc. Q1 FY2022 Earnings Call
Revenue
$47.50M
▲ 210.5% YoY Diluted EPS
$6.80
▲ 1033.3% YoY Gross margin
60.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-30
ProPhase Labs, Inc. Q4 FY2021 Earnings Call
Revenue
$45.14M*
▲ 774.3% YoY Gross margin
54.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-12
ProPhase Labs, Inc. Q3 FY2021 Earnings Call
Revenue
$9.50M
▲ 147.4% YoY Diluted EPS
$-2.60
Gross margin
41.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-13
ProPhase Labs, Inc. Q2 FY2021 Earnings Call
Revenue
$9.10M
▲ 151.2% YoY Diluted EPS
$-0.90
▼ 1000% YoY Gross margin
49.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-05
ProPhase Labs, Inc. Q1 FY2021 Earnings Call
Revenue
$15.30M
▲ 710.4% YoY Diluted EPS
$0.60
Gross margin
58.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
ProPhase Labs, Inc. Q4 FY2020 Earnings Call
Revenue
$5.16M*
▲ 64.4% YoY Gross margin
36.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–20 of 20 earnings calls